Key result
GDF-15 upregulation linked to adverse CV events and enhances risk assessment alongside other biomarkers.
Why the study?
Variability between measurement methods and potential interference from genetic variants highlight the need for standardization of GDF-15 assessment in cardiovascular diseases.
Design
Review
Authors
Loading...
May support adjunctive risk models in research; leaves open standardization and prospective validation before clinical use.
Lombardi et al. (2026) studied this question. GDF-15 upregulation is associated with adverse cardiovascular events and can enhance risk assessment and early detection when combined with other biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: